Analytical Data
-
Gene name
CD7
- Application
-
Alternative Names
GP40; LEU9; TP41; Tp40; p41 Protein; T-cell Antigen CD7; T-cell Leukemia Antigen; T-cell surface antigen Leu-9
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P09564
-
Expression Region
Ala26~Pro180
-
Molecular Weight
25kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD7 is a glycoprotein primarily expressed on the surface of T cells and some natural killer (NK) cells, playing a crucial role in the immune response and cell signaling. The study of CD7 has gained significant interest due to its involvement in various hematological malignancies, including T-cell leukemias and lymphomas. Understanding the molecular mechanisms and pathways involving CD7 can provide insights into tumor biology and potential therapeutic targets. Efforts to develop CD7 recombinant proteins have opened avenues for research into their functional roles in immunotherapy. By generating CD7 chimeric proteins or fusion constructs, scientists aim to elucidate the protein's interactions, signaling pathways, and its influence on immune cell activation. Furthermore, these recombinant proteins can serve as valuable tools in the development of CD7-targeted therapies, such as bispecific antibodies or CAR T-cell treatments, enhancing the specificity and effectiveness of treatments for CD7-positive malignancies. The study of CD7 recombinant proteins thus represents a promising frontier in immuno-oncology, paving the way for novel strategies to combat T-cell-related disorders.
